Navigation Links
First United Kingdom Patients Treated With Percutaneous MitraClip(R) System
Date:11/26/2008

MENLO PARK, Calif., Nov. 26 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today that the first three patients have been successfully treated with the MitraClip(R) system at the University of Hull, Castle Hill Hospital in the United Kingdom. The MitraClip(R) system is the first commercially available medical device which provides a non-surgical mitral valve repair option for patients suffering from the effects of mitral regurgitation (MR).

Mitral regurgitation is the most common type of heart valve insufficiency in Europe and the United States, affecting millions of people worldwide. In the vast majority of patients, the MR is untreated, requiring the heart to work harder and ultimately leading to heart failure.

The first patients in the United Kingdom were treated by the team led by Farqad Alamgir, M.D., consultant cardiologist for the Trust; Simon Thackray, M.D., consultant cardiologist; Raj Nair, M.D., cardiology registrar and Andrew L. Clark, M.D., reader and honorary consultant in cardiology.

"This technology is cutting edge and may transform the way many of our patients receive heart surgery," said Dr. Alamgir. "The MitraClip(R) therapy reduces many of the risks and trauma currently associated with open heart surgery. Currently, patients with MR only have one option. Now they have a second option which may not require them to have surgery. I believe the MitraClip(R) system will not only play a key role for non-surgical MR patients, but should also be considered as a therapy for select surgical candidates."

Evalve received CE Mark approval for the MitraClip(R) system this year and began commercial sales in Europe in September, 2008. The company has worked with hospitals across Europe to establish training programs in support of the European roll out.

"Suitable patients now have a less inv
'/>"/>

SOURCE Evalve, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... A challenge donation from the Bezos family ... total to more than $7 million for Fred Hutchinson ... of the live auction during which guests raise their ... million to be directed toward the Hutchinson Center,s work ... ,, The black-tie Gala took place Dec. 5 ...
(Date:12/6/2009)... Ingelheim today announced results from the RE-COVER(TM) study ... thrombin inhibitor (DTI),(2) compared to dose-adjusted warfarin in ... trial were presented at the 51st American Society ... in the New England Journal of Medicine ... outcome of the trial, six month incidence of ...
(Date:12/4/2009)... National Institute of Standards and Technology (NIST) and the ... introduce magnetic impurities in a semiconductor crystal by prodding ... a recent paper,* this technique will enable researchers to ... time to learn about its electrical and magnetic properties ...
(Date:12/4/2009)... Bulletin Board: VIVK) today confirmed that its shareholders of ... of shares of common stock of HealthAmerica, Inc. that ... HealthAmerica is a private Nevada corporation of which Vivakor ... the record date. The distribution date is still expected ...
Breaking Biology Technology:34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 234th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6NIST researchers put a new spin on atomic musical chairs 2Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3
... world leader in the,field of in vitro diagnostics, ... 2009 with ICNet Systems, Inc., a leading international ... software. , "Microbiology and ... said Herb Steward, executive vice president and general,manager, ...
... and improved seizure freedom versus placebo when ... (AEDs)- Phase III study supports recent U.S. ... Jan. 27 The new antiepileptic drug ... adult partial-onset epilepsy patients whose seizures were ...
... -- Pharmaxis Ltd (AXS: PXS,Nasdaq: PXSL ) ... the afternoon of Wednesday, 28th January 2009. Dr. ... to review the quarter,and answer investor questions. , ... 29th January at 8:30am (Sydney),(Wednesday, 28th January at 4:30pm ...
Other Biology Technology:bioMerieux Introduces Surveillance Tool to Fight Healthcare-Associated Infections 2bioMerieux Introduces Surveillance Tool to Fight Healthcare-Associated Infections 3Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 2Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 3Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 4Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 5
(Date:12/5/2009)... become the source of more of humanity,s food if ... according to a study published in the December 2009 ... population continues to grow, lack of fresh water and ... able to meet food demand, according to Carlos M. ... and his seven coauthors. Freshwater aquaculture, which is largely ...
(Date:12/5/2009)... research into venom produced by snakes and spiders, venomous ... mystery. Now, a study of 158 catfish species, published ... , has catalogued the presence of venom glands and ... from the University of Michigan, USA, carried out the ... to elucidate the diversity and distribution of venomous catfish. ...
(Date:12/4/2009)... a battle zone. Cells constantly compete with one another for ... win this competition is well known to be the survival ... space and survival is not as clear. A study on ... Science by Johns Hopkins researchers describes how stem cells ...
Breaking Biology News(10 mins):Stem cells battle for space 2New York City Immigration Lawyers Bretz 26amp 3B Coven LLP Prevent Deportation of South Korean Nurse 58444 1New York City Immigration Lawyers Bretz 26amp 3B Coven LLP Prevent Deportation of South Korean Nurse 58444 2New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 1New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 2New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 3New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 4New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 5Force Sensor Manufacturer Tekscan Inc Wins 26quot 3BBest of Tradeshow 26quot 3B for MDM Minneapolis Exhibition 58440 1Force Sensor Manufacturer Tekscan Inc Wins 26quot 3BBest of Tradeshow 26quot 3B for MDM Minneapolis Exhibition 58440 2Force Sensor Manufacturer Tekscan Inc Wins 26quot 3BBest of Tradeshow 26quot 3B for MDM Minneapolis Exhibition 58440 3
... a newly developed robot capable of diving as ... ocean, has been successfully completed by scientists and ... and the University of Washington (UW). , The ... sites for seafloor instruments that will be deployed ...
... sensitivity of days-old fish embryos to create a tool ... By measuring rates of oxygen use in developing fish, ... technology could reveal the presence of minute levels of ... harm. It could be used as an early warning ...
... Blacksburg, Va. -- A new technology, using electric pulses ... Briefs as one of seven key technological breakthroughs of ... procedure to the marketplace. One of its lead ... Virginia TechWake Forest University School of Biomedical Engineering and ...
Other Biology News:Robot vehicle surveys deep sea off Pacific Northwest 2Robot vehicle surveys deep sea off Pacific Northwest 3Using live fish, new tool a sentinel for environmental contamination 2Using live fish, new tool a sentinel for environmental contamination 3Commercialization aim of grant supporting technology that destroys cancer cells 2
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... proto-oncogene was first identified as the cellular homolog ... B and Jun D have been shown to ... regions, which are involved in dimerization and DNA ... in transcriptional activation, diverge. Antigen: ...
Biology Products: